No retraction, correction or concern found when last checked on Oct 29, 2026.

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

Linde Schoenmaker, Dominik Witzigmann, Jayesh A. Kulkarni and 4 more

International Journal of Pharmaceutics · 2021 · Review · CC BY

doi:10.1016/j.ijpharm.2021.120586

Abstract

A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally improve mRNA-LNP product stability and thereby ease the temperature conditions for storage. In this review we discuss proposed structures of mRNA-LNPs, factors that impact mRNA-LNP stability and strategies to optimize mRNA-LNP product stability. Analysis of mRNA-LNP structures reveals that mRNA, the ionizable cationic lipid and water are present in the LNP core. The neutral helper lipids are mainly positioned in the outer, encapsulating, wall. mRNA hydrolysis is the determining factor for mRNA-LNP instability. It is currently unclear how water in the LNP core interacts with the mRNA and to what extent the degradation prone sites of mRNA are protected through a coat of ionizable cationic lipids. To improve the stability of mRNA-LNP vaccines, optimization of the mRNA nucleotide composition should be prioritized. Secondly, a better understanding of the milieu the mRNA is exposed to in the core of LNPs may help to rationalize adjustments to the LNP structure to preserve mRNA integrity. Moreover, drying techniques, such as lyophilization, are promising options still to be explored.

References 85

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** · 2012
No notice
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses · 2018
No notice
41.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
42.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
43.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
44.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
45.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
46.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
47.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
48.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
49.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
50.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
51.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
52.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
53.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
54.
mRNA structure regulates protein expression through changes in functional half-life · 2019
No notice
55.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
56.
The promise of mRNA vaccines: a biotech and industrial perspective · 2020
No notice
57.
Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA · 2020
Corrected
58.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
59.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
60.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
61.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
62.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
63.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
64.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
65.
Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice · 2020
No notice
66.
An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates · 2020
No notice
67.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
68.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
69.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
70.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
71.
The effects of PEGylation on LNP based mRNA delivery to the eye · 2020
No notice
72.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
73.
Addressing the Cold Reality of mRNA Vaccine Stability · 2021
No notice
74.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
75.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
76.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
77.
Nanomaterial Delivery Systems for mRNA Vaccines · 2021
No notice
78.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
79.
Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles · 2021
No notice
80.
Encapsulation state of messenger RNA inside lipid nanoparticles · 2021
No notice
81.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
82.
Theoretical basis for stabilizing messenger RNA through secondary structure design · 2021
No notice
83.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
84.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
85.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 19

Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications · 2025
Not checked
Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets · 2024
No notice
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders · 2024
Corrected
A Comprehensive Review of mRNA Vaccines · 2023
No notice
Research Advances on the Stability of mRNA Vaccines · 2023
No notice
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines · 2023
No notice
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective · 2023
No notice
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2 · 2023
No notice
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
No notice
mRNA-based therapeutics: powerful and versatile tools to combat diseases · 2022
No notice
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions · 2022
No notice
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging · 2022
No notice
Advances in COVID-19 mRNA vaccine development · 2022
No notice
Recent Advances in Lipid Nanoparticles for Delivery of mRNA · 2022
No notice
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? · 2022
No notice
Antimicrobial Photodynamic Therapy: Latest Developments with a Focus on Combinatory Strategies · 2021
No notice
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines · 2021
No notice
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics · 2021
No notice
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.